Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 17/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16669705 | 0.92 | SUV39H2 (0.43) | SUV39H2RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL16674755 | 0.89 | SUV39H2 (0.56) | SUV39H2 | |
| SCHEMBL15086168 | 0.82 | SUV39H2 (0.54) | SUV39H2 | |
| SCHEMBL30708168 | 0.80 | SUV39H2 (0.48) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL15069225 | 0.80 | SUV39H2 (0.48) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL15068854 | 0.79 | RAB9A (0.43) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL16669697 | 0.79 | RAB9A (0.44) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL15068750 | 0.78 | RAB9A (0.43) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL15067188 | 0.77 | SUV39H2 (0.45) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL15069258 | 0.76 | RAB9A (0.41) | SUV39H2RAB9AKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | claimed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | SUV39H2 708/4885RAB9A 3292/4885KDM4E 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.